Biblio

Export 130 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is tau Proteins  [Clear All Filters]
2016
M. Babić Leko, Borovečki, F., Dejanović, N., Hof, P. R., and Šimić, G., “Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
R. A. Stern, Tripodis, Y., Baugh, C. M., Fritts, N. G., Martin, B. M., Chaisson, C., Cantu, R. C., Joyce, J. A., Shah, S., Ikezu, T., Zhang, J., Gercel-Taylor, C., and Taylor, D. D., “Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1099-109, 2016.
B. N. Dugger, Whiteside, C. M., Maarouf, C. L., Walker, D. G., Beach, T. G., Sue, L. I., Garcia, A., Dunckley, T., Meechoovet, B., Reiman, E. M., and Roher, A. E., “The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 345-56, 2016.
E. Morenas-Rodriguez, Cervera-Carles, L., Vilaplana, E., Alcolea, D., Carmona-Iragui, M., Dols-Icardo, O., Ribosa-Nogué, R., Muñoz-Llahuna, L., Sala, I., M Sánchez-Saudinós, B., Blesa, R., Clarimón, J., Fortea, J., and Lleo, A., “Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.”, J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
X. - P. Hong, Chen, T., Yin, N. - N., Han, Y. - M., Yuan, F., Duan, Y. - J., Shen, F., Zhang, Y. - H., and Bin Chen, Z. -, “Puerarin Ameliorates D-Galactose Induced Enhanced Hippocampal Neurogenesis and Tau Hyperphosphorylation in Rat Brain.”, J Alzheimers Dis, vol. 51, no. 2, pp. 605-17, 2016.
M. Elahi, Hasan, Z., Motoi, Y., Matsumoto, S. - E., Ishiguro, K., and Hattori, N., “Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1209-24, 2016.
G. Koch, Di Lorenzo, F., Del Olmo, M. Fernandez, Bonní, S., Ponzo, V., Caltagirone, C., Bozzali, M., and Martorana, A., “Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression.”, J Alzheimers Dis, vol. 50, no. 2, pp. 605-16, 2016.
J. Bennett, Burns, J., Welch, P., and Bothwell, R., “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
J. - P. Morin, Cerón-Solano, G., Velázquez-Campos, G., Pacheco-López, G., Bermúdez-Rattoni, F., and Díaz-Cintra, S., “Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 69-79, 2016.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
N. Pierrot, Lhommel, R., Quenon, L., Hanseeuw, B., Dricot, L., Sindic, C., Maloteaux, J. - M., Octavea, J. - N., and Ivanoiu, A., “Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.
C. Hyoung Lyoo, Cho, H., Choi, J. Yong, Hwang, M. Song, Hong, S. Kyoon, Kim, Y. Joong, Ryu, Y. Hoon, and Lee, M. Sik, “Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis.”, J Alzheimers Dis, vol. 51, no. 3, pp. 671-5, 2016.
L. García Barrado, Coart, E., Vanderstichele, H. M. J., and Burzykowski, T., “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
M. Xie, Han, Y., Yu, Q., Wang, X., Wang, S., and Liao, X., “UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein.”, J Alzheimers Dis, vol. 49, no. 2, pp. 353-63, 2016.
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
2014
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
S. Hoon Choi, Kim, Y. Hye, Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., and Kim, D. Yeon, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
2013
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C., “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
C. R. Jack, Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., and Trojanowski, J. Q., “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
2012
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
L. Calderón-Garcidueñas, Kavanaugh, M., Block, M., D'Angiulli, A., Delgado-Chávez, R., Torres-Jardón, R., González-Maciel, A., Reynoso-Robles, R., Osnaya, N., Villarreal-Calderon, R., Guo, R., Hua, Z., Zhu, H., Perry, G., and Diaz, P., “Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.”, J Alzheimers Dis, vol. 28, no. 1, pp. 93-107, 2012.
A. de Calignon, Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., Spires-Jones, T. L., and Hyman, B. T., “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
2011
M. T. Fodero-Tavoletti, Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., Gong, S., Adlard, P. A., Barnham, K. J., Rowe, C. C., Masters, C. L., Kudo, Y., Cappai, R., Yanai, K., and Villemagne, V. L., “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
C. R. Jack, Vemuri, P., Wiste, H. J., Weigand, S. D., Aisen, P. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Petersen, R. C., Weiner, M. W., and Knopman, D. S., “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.

Pages